<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087876</url>
  </required_header>
  <id_info>
    <org_study_id>DZB-iCCA-EA</org_study_id>
    <nct_id>NCT04087876</nct_id>
  </id_info>
  <brief_title>Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations</brief_title>
  <official_title>Expanded Access Use of Derazantinib for Patients With Locally Advanced, Inoperable or Metastatic iCCA Harbouring FGFR Genomic Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <brief_summary>
    <textblock>
      Basilea is providing expanded access to derazantinib for patients with locally advanced,
      inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations
      on a patient by patient basis while clinical development of derazantinib is ongoing.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>derazantinib</intervention_name>
    <description>derazantinib will be administered orally</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all other treatment options have been exhausted

          -  patient is ineligible for any ongoing trials or is geographically inaccessible to
             trials including an ongoing trial with derazantinib

          -  there is reason to believe that the potential benefit of receiving derazantinib
             outweighs the risk of treatment with an investigational drug product

          -  patient is willing and able to provide written informed consent

          -  if applicable, regulatory approval by the appropriate jurisdiction is obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Frédérique Cantero, MD</last_name>
    <phone>+41768302499</phone>
    <email>frederique.cantero@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan Braun, MD</last_name>
    <phone>+41616061225</phone>
    <email>stephan.Braun@basilea.com</email>
  </overall_contact_backup>
  <link>
    <url>https://www.basilea.com/</url>
    <description>Basilea Website</description>
  </link>
  <link>
    <url>https://www.clinicaltrials.gov/ct2/show/NCT03230318?cond=derazantinib&amp;rank=1</url>
    <description>CTgov link to ongoing study with derazantinib</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intrahepatic cholangiocarcinoma</keyword>
  <keyword>iCCA</keyword>
  <keyword>Metastatic cholangiocarcinoma</keyword>
  <keyword>FGFR genomic alteration</keyword>
  <keyword>biliary cancer</keyword>
  <keyword>bile duct cancer</keyword>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

